Mirador Therapeutics closed a $250 million Series B to accelerate its precision-immunology pipeline and signaled plans to consider an IPO later in the year. The financing will support clinical development across multiple immune-disease programs and expand Mirador’s platform capabilities. Company executives told Endpoints News that the round positions Mirador to enter later-stage studies and commercial-readiness planning. The raise illustrates continued large private financings for immunology startups amid a cautious but improving biotech financing environment.